3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Sarcoma, Ewing
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Lymphoma
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
11
Rituximab
10
Prednisone
8
Lenalidomide
8
Vincristine
7
Doxorubicin
7
Bendamustine Hydrochloride
6
obinutuzumab
5
Magnetic Resonance Spectroscopy
4
fludarabine
3
Whole-Body Irradiation
3
Specimen Handling
3
R-CHOP protocol
3
Cyclosporine
3
Biopsy
3
zanubrutinib
2
fludarabine phosphate
2
Radiotherapy
2
Prednisolone
2
Peripheral Blood Stem Cell Transplantation
2
Oxaliplatin
2
Mycophenolic Acid
2
Melphalan
2
Gemcitabine
2
Etoposide
2
Cytarabine
2
venetoclax
1
umbralisib
1
treosulfan
1
tazemetostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
etoposide phosphate
×
30 days
×
Clear all
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled